key: cord-0939165-qkn63sgp
authors: Ocmant, Annick; Roisin, Sandrine; De Meuter, Régis; Brauner, Jonathan
title: Clinical performance of the Advia Centaur anti‐SARS‐CoV‐2 chemiluminescent immunoassay related to antibody kinetics
date: 2021-01-27
journal: J Med Virol
DOI: 10.1002/jmv.26800
sha: 55530243c6918b688604b79efbc3c644fce8cd62
doc_id: 939165
cord_uid: qkn63sgp

In the wake of the COVID-19 pandemic, the antibody responses to SARS-CoV-2 virus have received a huge interest for diagnostic or epidemiological purposes. This article is protected by copyright. All rights reserved.

To the Editor, In the wake of the COVID-19 pandemic, the antibody responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus have received a huge interest for diagnostic or epidemiological purposes. 1 Therefore, a range of serological tests detecting specific antibodies to SARS-CoV-2 have emerged, but their performances depend on several factors, such as the methodology of the immunoassay, the viral antigen used for antibody binding, and the isotype detection. 2 In this study, the detection of total antibodies (including immunoglobulin G [IgG] and IgM) to SARS-CoV-2 has been performed on the Advia Centaur XP platform by using a new commercial immunoassay from Siemens Healthineers®. This chemiluminescent technique allows the detection of antibodies that recognized a recombinant receptor binding domain (RBP) protein from the coronavirus Spike protein S1. Antibodies targeting the viral RBP tend to have neutralizing capacities and to confer protective immunity. 3 The Siemens SARS-CoV-2 assay was carried out according to the manufacturer's instructions and its recommended cutoff of 1 was applied for results interpretation (index ≥ 1 means positive while index <1 is negative).

The local ethical committee of the CHU Tivoli approved this study. 

SARS-CoV-2 serology: much hype, little data

Diagnostic efficacy of anti-SARS-CoV-2 IgG/IgM test for Covid-19: a meta-analysis

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

Clinical performance of the Centaur XP anti-SARS-CoV-2 immunoassay: kinetics of the antibody response in COVID patients relative to time since positive RT-PCR/or COVID-antigen (A) and to time since symptom onset (B) as compared with prepandemic controls. RT-PCR, reverse transcription polymerase chain reaction

The authors declare that there are no conflict of interests.

The data that support the findings of this study are available from the corresponding author upon reasonable request.